Biolargo Stock Working Capital
| BLGO Stock | USD 0.29 0.01 3.33% |
BioLargo fundamentals help investors to digest information that contributes to BioLargo's financial success or failures. It also enables traders to predict the movement of BioLargo OTC Stock. The fundamental analysis module provides a way to measure BioLargo's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLargo otc stock.
BioLargo |
BioLargo OTC Stock Working Capital Analysis
BioLargo's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current BioLargo Working Capital | 1.04 M |
Most of BioLargo's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLargo is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, BioLargo has a Working Capital of 1.04 M. This is 99.85% lower than that of the Chemicals sector and 99.94% lower than that of the Materials industry. The working capital for all United States stocks is 99.93% higher than that of the company.
BioLargo Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLargo's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of BioLargo could also be used in its relative valuation, which is a method of valuing BioLargo by comparing valuation metrics of similar companies.BioLargo is currently under evaluation in working capital category among its peers.
BioLargo Fundamentals
| Return On Equity | -3.63 | |||
| Return On Asset | -0.69 | |||
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.16) % | |||
| Current Valuation | 52.87 M | |||
| Shares Outstanding | 275.42 M | |||
| Shares Owned By Insiders | 14.70 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Earning | (4.54) X | |||
| Price To Book | 10.61 X | |||
| Price To Sales | 11.52 X | |||
| Revenue | 2.53 M | |||
| Gross Profit | 1.1 M | |||
| EBITDA | (6.64 M) | |||
| Net Income | (7.08 M) | |||
| Cash And Equivalents | 1.23 M | |||
| Total Debt | 367 K | |||
| Debt To Equity | 0.72 % | |||
| Current Ratio | 1.82 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (3.94 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 0.29 | |||
| Number Of Employees | 31 | |||
| Beta | -0.0345 | |||
| Market Capitalization | 64.59 M | |||
| Total Asset | 3.02 M | |||
| Retained Earnings | (89.68 M) | |||
| Working Capital | 1.04 M | |||
| Current Asset | 1.87 M | |||
| Current Liabilities | 831 K | |||
| Z Score | 57.8 | |||
| Net Asset | 3.02 M |
About BioLargo Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLargo's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLargo using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLargo based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.